Antibe resumes ATB-346 development2015-03-11 08:27 ET - News Release
Mr. Dan Legault reports
ANTIBE THERAPEUTICS PROVIDES AN UPDATE ON ITS DATA REVIEW AND CORPORATE STRATEGY
Antibe Therapeutics Inc. has completed the process of collecting and reviewing its phase 1 data, further to its Jan. 16, 2015, news release. As a result, Antibe has resumed the development of ATB-346.
ATB-346's pharmacokinetic profile, coupled with data on cyclooxygenase inhibition in humans (an efficacy biomarker), suggests a target therapeutic dose at or below 250 milligrams daily, a much lower level than initially anticipated. It also provides a possible explanation for the safety issues observed at the 750-milligram and 1,500-milligram doses. At a dose of 250 milligrams given once daily for 14 days, ATB-346 was safe and well tolerated in the phase 1 study.
Accordingly, the company has concluded its phase 1 study and plans to conduct additional validating studies prior to continuing with a full phase 2 program. The company has made significant reductions in its overheads and will concentrate its resources on completing the above studies.